Table 1.
Trials of basal insulin analogues in insulin-naïve patients with type 2 diabetes
| Author | HbA1c |
FPG |
Hypoglycemia | Weight gain (kg) | Dose | |||
|---|---|---|---|---|---|---|---|---|
| Baseline | End | Baseline | End | |||||
| Hermansen 2006 | Detemir NPH | 8.6 | 6.8 | 11.1 | 6.9 | RR 0.53a | 1.2a | BD |
| 8.5 | 6.6 | 10.8 | 6.6 | 2.8 | ttt | |||
| Philis-Tsimikas 2006 | Detemir am or pm NPH | 9.1 | 7.5 | 11.5 | 8.6 | RR 0.68 | 1.2 | OD |
| 8.9 | 7.4 | 10.8 | 7.2 | RR 0.47a | 0.7b | ttt | ||
| 9.2 | 7.4 | 11.5 | 7.8 | 1.6 | ||||
| Yki-Jarvinen 2000 | Glargine NPH | 9.1 | 8.34 | ~34%c | 2.57 | OD | ||
| 8.9 | 8.24 | ~42% | 2.34 | |||||
| Massi-Benedetti 2003 | Glargine NPH | 9.0 | 8.5 | 13.0 | 9.6 | 35% | 2.01 | OD |
| 8.9 | 8.5 | 13.1 | 9.8 | 41% | 1.88 | |||
| Fritsche 2003 | Glargine am or pm NPH | 9.1 | 7.8a | 12.1 | 7.0 | 74% | 3.9 | OD |
| 9.1 | 8.1b | 12.0 | 6.8 | 68% | 3.7 | |||
| 9.1 | 8.3 | 12.2 | 6.9 | 75% | 2.9 | |||
| Riddle 2003 | Glargine NPH | 8.61 | 6.96 | 11.0 | 6.5 | 13.9%c | 3.0 | OD |
| 8.56 | 6.97 | 10.8 | 6.7 | 17.7 e/pt/yr | 2.8 | ttt | ||
| Eliaschewitz 2006 | Glargine NPH | 9.03 | 7.65 | 11.2 | 6.4 | 52.8%c | Not reported | OD |
| 9.21 | 7.78 | 10.8 | 6.6 | 62.8% | ttt | |||
a
Notes: Between-treatment comparison: p < 0.001;
b
p < 0.01;
c
p < 0.05.
Abbreviations: ttt, treat-to-target study; hypoglycemia RR, relative risk; %, % of patients experiencing hypos; e/pt/y, events per patient year.